


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

(51) International Patent Classification ⁵ : C07C 403/20		A1	(11) International Publication Number: WO 94/22818
			(43) International Publication Date: 13 October 1994 (13.10.94)
(21) International Application Number: PCT/US94/00595		(81) Designated States: CA, FI, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 28 January 1994 (28.01.94)			
(30) Priority Data: 08/042,927 5 April 1993 (05.04.93) US		Published With international search report.	
(60) Parent Application or Grant (63) Related by Continuation US 08/042,927 (CON) Filed on 5 April 1993 (05.04.93)			
(71) Applicant (for all designated States except US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).			
(72) Inventor; and (75) Inventor/Applicant (for US only): COE, Jotham, Wadsworth [US/US]; 151 Lamphere Road, Mystic, CT 06355 (US).			
(74) Agents: RICHARDSON, Peter, C. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).			

CC1(C)C=CC(=C/C=C/C(=C/C=C/C(=C/C=C/C(=O)O)/C)/C)/C1

(II)



A method for preparing a compound of formula (II) comprising photolyzing a compound of formula (I).

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

5

METHOD FOR THE PREPARATION OF 9-CIS RETINOIC ACIDBackground of the Invention

The present invention relates to a process for the preparation of 9-cis retinoic acid. That compound is useful in the treatment of dermal, neoplastic and immunological disorders.

Traditionally, 9-cis retinoic acids have been obtained as a result of non-selective olefination reactions in retinoic acid syntheses. J. Am. Chem. Soc., 77, 4111 (1955), refers to the synthesis of the 6-cis-vitamin A acid through the Knoevenagel condensation reaction of β -ionylideneacetaldehyde with an ester of β -methylglutaconic acid catalyzed by a weak base. German Patent No. 1,050,763 and R. Trav. Chim., 68, 609 (1949) refer to the synthesis of the 9-cis form of vitamin A, as the minor isomer, utilizing the Reformatsky and Wittig condensation reactions, respectively.


The present method exploits the highly crystalline nature of 9-cis retinoic acid to enrich it from a mixture of isomers produced by the photolysis of any isomer of retinoic acid.

Summary of the Invention

The present invention relates to a method for the preparation of a compound of the formula

25


30



35

comprising photolyzing a compound of the formula

-2-



5


I

The present invention also relates to a method of crystallizing 9-cis retinoic acid directly from the reaction solution.

Detailed Description of the Invention

The following reaction scheme illustrates the preparation of the compound of the present invention.

5




I

10



15



II

20

25

COOH

The retinoic acid compound of formula I is converted to the corresponding 9-cis retinoic acid of formula II by refluxing and photolyzing I in solvent, preferably for a time period between about 19 hours to about 29 hours, more preferably about 24 hours, under inert reaction conditions. Photolysis of the trans retinoic acid compound of formula I occurs at wavelengths between about 250 nanometers to about 380 nanometers, preferably about 345 nanometers, through the use of a 150 watt to 300 watt tungsten filament lamp. Acetonitrile is the preferred solvent, however, other suitable solvents include C₁-C₅alkanol, ethyl acetate, tetrahydrofuran, dioxane, carbon tetrachloride, ethylene glycol dimethyl ether and dimethylacetamide. Upon completion of this reaction step, the reaction mixture is allowed to cool to room temperature and the desired 9-cis retinoic acid compound of formula II is recovered from solution in the form of a crystalline precipitate.

The 9-cis retinoic acid compound is useful in the treatment of dermal, neoplastic and immunological disorders.

15

EXAMPLE 1

Trans-retinoic acid (4.0 grams, 13.3 mmol) was dissolved in high pressure liquid chromatography grade acetonitrile (1.5 liters) in a 3-liter single neck flask equipped with a condenser, a nitrogen inlet tube and a magnetic stirrer. The stirred dispersion dissolved at reflux under exposure to a 300 Watt tungsten filament lamp for 24 hours. After cooling, the solvent was removed on a rotary evaporator (bath temperature 35-40°C, aspirator vacuum) until 800 mL of solvent has been collected. The reaction mixture was allowed to stand at ambient temperature for 30 minutes. Crystallization then began and was allowed to proceed for 10 minutes. Filtration provided 564 mg of a yellow solid. Recrystallization from ethanol provided 197 mg of 9-cis retinoic acid (m.p. 187-189°C, ethanol), 5% yield. Reequilibration of the mother liquors under the above conditions provided 177 mg of additional material.

CLAIMS

1. A method of preparing a compound of the formula



5

10

15

comprising photolyzing a compound of the formula

20



- 25 2. A method according to claim 1, wherein the 9-cis retinoic acid of formula II is crystallized directly from the reaction solution.
3. A method according to claim 1, wherein the retinoic acid of formula I is trans retinoic acid.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 94/00595

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C07C403/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,4 026 778 (M. LALONDE ET AL.) 31 May 1977 see the whole document	1-3
X	CHEMICAL ABSTRACTS, vol. 119, no. 5, 2 August 1993, Columbus, Ohio, US; abstract no. 049677, DAWSON M I ET AL 'Preparation of 9-cis-retinoic acid [11,12-3H(N)] by photochemical isomerization' see abstract & J. LABELLED COMPD. RADIOPHARM. (JLCRD4,03624803);93; VOL.33 (3); PP.245-7 SRI INT.;MENLO PARK; 94025; CA; USA (US)	1,3

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

18 April 1994

Date of mailing of the international search report

28.04.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Bonnevalle, E

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

CT/US 94/00595

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4026778	31-05-77	CH-A- 605724	13-10-78
		AT-B- 350743	11-06-79
		BE-A- 835334	07-05-76
		DE-A,B,C 2548883	13-05-76
		FR-A,B 2291191	11-06-76
		GB-A- 1527909	11-10-78
		JP-C- 1240842	26-11-84
		JP-A- 51070749	18-06-76
		JP-B- 59015907	12-04-84
		NL-A- 7512152	14-05-76

BEST AVAILABLE COPY